Lilly cleared to sell US facility to Covance

7 September 2008

US drug major Eli Lilly has been cleared by the Federal Trade Commission to sell its Greenfield, Indiana, research facility to Covance, a provider of development services, for $50.0 million.

The move is part of a $1.6 billion, 10-year deal between the drug major and Covance to restructure Lilly's R&D facilities (Marketletter August 11). The New Jersey-based development firm will use the facility to conduct clinical trial work for Lilly among other biotechnology and pharmaceutical companies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight